Study Title

Exploring the Potential for 18F-fluoro-ethyl-tyrosine (18F-FET) to Enable Wider Access to Molecular Imaging for Patients With Pituitary Adenomas (FET-pit-PET Study)

Study Details

Description:

The goal of this single centre pilot study is to explore whether 18F-fluoro-ethyl-tyrosine PET (FET-PET) yields comparable findings to 11C-methionine PET (Met-PET) for the localisation of pituitary tumours.

Sponsor:

University of Cambridge

Contacts:

James MacFarlane

jm2267@medschl.cam.ac.uk

01223 250882

Government Study Link:

NCT06584123 - Click here to see study on

ClinicalTrials.gov

Drug Details

18F-fluoro-ethyl-tyrosine PET (FET-PET)
Isotopes:
    FLUORINE-18
    Radioisotope: F-18
    Theranostic Role: PET Imaging
    T1/2 (Half-Life): 1.8 Hours
    Decay Mode: POSITRON β+ (96.7%), ELECTRON CAPTURE (3.3%), GAMMA 511 keV
    Energy: Eβ+ 635 keV
    Range: N/A
    Decay Daughters: O18 (Stable)
    Status: FDA Approvals: FDG (Cancer 2005): GLUDEF®, METATRACE® AXUMIN® (2016), PYLARIFY® (2023), POSLUMA® (2024)
  • FLUORINE-18
Target: Amino Acid Transport
11C-methionine PET (Met-PET)
Isotopes:
    CARBON-11
    Radioisotope: C-11
    Theranostic Role: PET Imaging, SPECT Imaging
    T1/2 (Half-Life): 20.4 Min
    Decay Mode: POSITRON β+ (99.8%), ELECTRON CAPTURE (0.2%), GAMMA
    Energy: max 0.96 MeV, mean 386 keV, Gamma 511 keV
    Range: N/A
    Decay Daughters: B11 (Stable)
    Status: FDA Approval: Carbon 11 Choline (2012)
  • CARBON-11
Target: Amino Acid Transport

© 2021 XCancer Software LLC

Contact XCancer: 402-991-8468